Ullman Lends Perspective on FDA Warning Letter

June 4, 2020 | Compliance Investigations & White Collar | Cannabis

Marc Ullman was quoted in a Nutraingredients-USA.com article entitled “Warning letter cites CBD’s regulatory status as leading issue.”

The Food and Drug Administration sent a warning letter to a supplement manufacturer regarding various failures in good manufacturing practice (GMP). For the first time, however, the letter cited the health claims made about CBD as the first issue. The article explores whether the move undermines FDA’s authority.

To read the article, click here.

Share this article:

Related News

Get legal updates and news delivered to your inbox